Rchr
J-GLOBAL ID：200901090905049167
Update date: Oct. 04, 2024
YUTAKA FUJIWARA
フジワラ ユタカ | YUTAKA FUJIWARA
Affiliation and department：
Job title：
Head
Research field (1)：
Respiratory medicine
Research theme for competitive and other funds (4)：
- 2022 - 2025 肺肉腫様癌に対するPD-1阻害薬治療の最適化と耐性機序の解明
- 2017 - 2019 小細胞肺癌におけるアムルビシン治療最適化のための効果予測因子の同定
- 2014 - 2017 The genomic and epigenomic landscape in thymic carcinoma
- 2013 - 2016 Personalized cancer chemotherapy: efficacy and safety based on pharmacokinetics and pharmacogenetics
Papers (164)：
-
Tomohisa Baba, Masahiko Kusumoto, Terufumi Kato, Yasuyuki Kurihara, Shinichi Sasaki, Katsunori Oikado, Yoshinobu Saito, Masahiro Endo, Yutaka Fujiwara, Hirotsugu Kenmotsu, et al. Correction to: Clinical and imaging features of interstitial lung disease in cancer patients treated with trastuzumab deruxtecan. International journal of clinical oncology. 2024. 29. 1. 78-79
-
Yutaka Fujiwara, Yasutoshi Kuboki, Masayuki Furukawa, Nobumasa Mizuno, Hiroki Hara, Tatsuya Ioka, Makoto Ueno, Yasuo Takahashi, Shunji Takahashi, Shinji Takeuchi, et al. FIGHT-102: A phase 1 study of pemigatinib in Japanese patients with advanced malignancies. Cancer medicine. 2023. 12. 9. 10597-10611
-
Satoru Iwasa, Takafumi Koyama, Makoto Nishino, Shunsuke Kondo, Kazuki Sudo, Kan Yonemori, Tatsuya Yoshida, Kenji Tamura, Toshio Shimizu, Yutaka Fujiwara, et al. First-in-human study of ONO-4578, an antagonist of prostaglandin E2 receptor 4, alone and with nivolumab in solid tumors. Cancer science. 2023. 114. 1. 211-220
-
Shigehisa Kitano, Yutaka Fujiwara, Toshio Shimizu, Satoru Iwasa, Kan Yonemori, Shunsuke Kondo, Akihiko Shimomura, Takafumi Koyama, Takahiro Ebata, Hiroki Ikezawa, et al. A feasibility study of lenvatinib plus pembrolizumab in Japanese patients with advanced solid tumors. Cancer chemotherapy and pharmacology. 2022. 90. 6. 523-529
-
Jun Sato, Toshio Shimizu, Takafumi Koyama, Satoru Iwasa, Akihiko Shimomura, Shunsuke Kondo, Shigehisa Kitano, Kan Yonemori, Yutaka Fujiwara, Kenji Tamura, et al. Dose Escalation Data from the Phase 1 Study of the Liposomal Formulation of Eribulin (E7389-LF) in Japanese Patients with Advanced Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research. 2022. 28. 9. 1783-1791
ｍore...
MISC (131)：
-
Keiko Goto, Yutaka Fujiwara, Takeshi Isobe, Naoko Chayahara, Naomi Kiyota, Toru Mukohara, Yukari Tsubata, Takamasa Hotta, Kenji Tamura, Noboru Yamamoto, et al. Pharmacokinetic study of the oral fluorouracil antitumor agent S-1 in patients with impaired renal function (vol 110, pg 1987, 2019). CANCER SCIENCE. 2020. 111. 4. 1437-1437
-
吉田和史, 藤原豊, 元井紀子, 本多隆行, 本多隆行, 渡辺俊一, 大江裕一郎, 河野隆志. 肺多形癌における遺伝学的・免疫学的プロファイリング. 日本肺癌学会総会号. 2018. 59th. 6. 575-575
-
吉田 和史, 藤原 豊, 元井 紀子, 本多 隆行, 渡辺 俊一, 大江 裕一郎, 河野 隆志. 肺多形癌の遺伝学的、免疫学的プロファイリング(Genomic and immunological profiling of pleomorphic carcinoma of the lung). 日本癌学会総会記事. 2018. 77回. 2461-2461
-
牧原 玲子, 前田 誠, 板橋 耕太, 塚本 多矩, 後藤 悌, 神田 慎太郎, 藤原 豊, 堀之内 秀仁, 牧野 好倫, 大江 裕一郎, et al. Dried plasma spot法を用いた抗悪性腫瘍薬の血中薬物濃度測定法. 臨床薬理の進歩. 2018. 39. 83-92
-
高 淳浩, 伊田 英恵, 神田 慎太郎, 佐藤 潤, 守田 亮, 村上 修司, 後藤 悌, 堀之内 秀仁, 藤原 豊, 山本 昇, et al. オシメルチニブが奏効したEGFR T790M変異陽性肺癌に合併した髄膜癌腫症の症例. 肺癌. 2018. 58. 2. 165-165
ｍore...
Professional career (1)：
Return to Previous Page
